Symbols / PMCB $0.78 +1.88% PharmaCyte Biotech, Inc.
PMCB Chart
About
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Fundamentals
Scroll to Statements| Market Cap | 8.37M | Enterprise Value | -11.29M | Income | -7.49M | Sales | — | Book/sh | 3.59 | Cash/sh | 1.91 |
| Dividend Yield | — | Payout | 0.00% | Employees | 2 | IPO | — | P/E | — | Forward P/E | -2.05 |
| PEG | — | P/S | — | P/B | 0.22 | P/C | — | EV/EBITDA | — | EV/Sales | — |
| Quick Ratio | 12.24 | Current Ratio | 12.33 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -0.89 | EPS next Y | -0.38 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2022-09-14 | ROA | -6.75% | ROE | -8.24% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 10.74M | Shs Float | 9.96M | Short Float | 0.96% |
| Short Ratio | 0.62 | Short Interest | — | 52W High | 1.51 | 52W Low | 0.63 | Beta | 0.41 | Avg Volume | 161.98K |
| Volume | 125.09K | Target Price | — | Recom | None | Prev Close | $0.77 | Price | $0.78 | Change | 1.88% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.78
Latest analyst target
3. DCF / Fair value
$-2.84
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.78
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2021-11-08 | init | HC Wainwright & Co. | — → Neutral | — |
- PMCB Stock Jumps 25% After Company Sells Stake In Femasys - Stocktwits hu, 05 Mar 2026 08
- PharmaCyte Biotech (PMCB) director awarded 119,170 stock options at $0.67 - Stock Titan hu, 02 Apr 2026 07
- QCLS News | Q/C TECHNOLOGIES INC (NASDAQ:QCLS) - ChartMill Fri, 17 Apr 2026 07
- PharmaCyte Biotech Shareholders Approve Governance and Equity Actions - The Globe and Mail Fri, 03 Apr 2026 07
- Jonathan Schechter buys PharmaCyte Biotech shares worth $48,232 - Investing.com Wed, 07 Jan 2026 08
- PharmaCyte Boosts Financial Position with Femasys Stake Sale - timothysykes.com Fri, 05 Dec 2025 08
- PharmaCyte Biotech: Is Growth Here to Stay? - StocksToTrade hu, 04 Dec 2025 08
- Director at PharmaCyte Biotech (PMCB) gets 119,170 options - Stock Titan hu, 02 Apr 2026 07
- PharmaCyte Biotech Shareholders Approve Governance and Equity Actions - TipRanks hu, 02 Apr 2026 07
- symbol__ Stock Quote Price and Forecast - CNN hu, 04 Jan 2024 12
- PMCB Forecast — Price Prediction for 2026. Should I Buy PMCB? - Intellectia AI Sat, 31 May 2025 08
- PharmaCyte Biotech, Inc. (PMCB) Q3 2026 10-Q Report: Financial Results, Stock Information, and SEC Filings - Minichart hu, 19 Mar 2026 07
- PharmaCyte Biotech (PMCB) director receives 119,170 stock options at $0.67 - Stock Titan hu, 02 Apr 2026 07
- PharmaCyte Biotech stock soars after successful Femasys stake sale - Investing.com ue, 25 Nov 2025 08
- AVXL Stock Jumps On Lower Q4 Loss, Anticipation For EMA Approval Of Alzheimer’s Drug - Stocktwits ue, 25 Nov 2025 18
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
4.38
-32.85%
|
6.52
+1.00%
|
6.46
+46.98%
|
4.39
|
| Research And Development |
|
0.44
+7.60%
|
0.41
-13.04%
|
0.47
-32.19%
|
0.69
|
| Selling General And Administration |
|
3.94
-35.55%
|
6.11
+28.63%
|
4.75
+120.37%
|
2.16
|
| General And Administrative Expense |
|
3.94
-35.55%
|
6.11
+28.63%
|
4.75
+120.37%
|
2.16
|
| Salaries And Wages |
|
—
|
1.14
+19.96%
|
0.95
+270.91%
|
0.26
|
| Other Gand A |
|
3.94
-35.55%
|
6.11
+60.83%
|
3.80
+100.05%
|
1.90
|
| Other Operating Expenses |
|
—
|
1.32
+7.08%
|
1.23
-20.05%
|
1.54
|
| Total Expenses |
|
4.38
-32.85%
|
6.52
+1.00%
|
6.46
+46.98%
|
4.39
|
| Operating Income |
|
-4.38
+32.85%
|
-6.52
-1.00%
|
-6.46
-46.98%
|
-4.39
|
| Total Operating Income As Reported |
|
-4.38
+48.62%
|
-8.52
-31.98%
|
-6.46
-46.98%
|
-4.39
|
| EBITDA |
|
-4.38
+32.85%
|
-6.52
-1.00%
|
-6.46
-52.30%
|
-4.24
|
| Normalized EBITDA |
|
-38.00
-288.37%
|
-9.78
-51.56%
|
-6.46
-52.30%
|
-4.24
|
| EBIT |
|
-4.38
+32.85%
|
-6.52
-1.00%
|
-6.46
-52.30%
|
-4.24
|
| Total Unusual Items |
|
33.62
+930.06%
|
3.26
|
0.00
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
33.62
+930.06%
|
3.26
|
0.00
|
0.00
|
| Special Income Charges |
|
-2.02
+43.48%
|
-3.57
|
0.00
|
0.00
|
| Other Special Charges |
|
2.02
|
—
|
—
|
—
|
| Impairment Of Capital Assets |
|
0.00
-100.00%
|
2.00
|
0.00
|
—
|
| Write Off |
|
—
|
1.57
|
0.00
|
—
|
| Net Income |
|
30.66
+9084.98%
|
0.33
+107.73%
|
-4.32
-1.81%
|
-4.24
|
| Pretax Income |
|
30.66
+9084.98%
|
0.33
+107.73%
|
-4.32
-1.81%
|
-4.24
|
| Net Non Operating Interest Income Expense |
|
1.42
-58.35%
|
3.40
+75.42%
|
1.94
+1133.01%
|
0.16
|
| Interest Expense Non Operating |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Net Interest Income |
|
1.42
-58.35%
|
3.40
+75.42%
|
1.94
+1133.01%
|
0.16
|
| Interest Expense |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Interest Income Non Operating |
|
1.42
-58.35%
|
3.40
+75.42%
|
1.94
+1129.03%
|
0.16
|
| Interest Income |
|
1.42
-58.35%
|
3.40
+75.42%
|
1.94
+1129.03%
|
0.16
|
| Other Income Expense |
|
33.62
+873.05%
|
3.45
+1610.36%
|
0.20
+4816.37%
|
-0.00
|
| Other Non Operating Income Expenses |
|
-0.00
-100.50%
|
0.19
-5.37%
|
0.20
+4816.37%
|
-0.00
|
| Gain On Sale Of Security |
|
35.64
+421.33%
|
6.84
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
7.06
+930.06%
|
0.69
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
30.66
+9084.98%
|
0.33
+107.73%
|
-4.32
-1.81%
|
-4.24
|
| Net Income From Continuing Operation Net Minority Interest |
|
30.66
+9084.98%
|
0.33
+107.73%
|
-4.32
-1.81%
|
-4.24
|
| Net Income From Continuing And Discontinued Operation |
|
30.66
+9084.98%
|
0.33
+107.73%
|
-4.32
-1.81%
|
-4.24
|
| Net Income Continuous Operations |
|
30.66
+9084.98%
|
0.33
+107.73%
|
-4.32
-1.81%
|
-4.24
|
| Normalized Income |
|
4.10
+282.51%
|
-2.24
+47.99%
|
-4.32
-1.81%
|
-4.24
|
| Net Income Common Stockholders |
|
23.36
+235.53%
|
-17.24
-299.38%
|
-4.32
-1.81%
|
-4.24
|
| Otherunder Preferred Stock Dividend |
|
6.16
-59.05%
|
15.05
|
0.00
|
—
|
| Diluted EPS |
|
3.19
+277.22%
|
-1.80
-718.18%
|
-0.22
+18.52%
|
-0.27
|
| Basic EPS |
|
3.19
+277.22%
|
-1.80
-718.18%
|
-0.22
+18.52%
|
-0.27
|
| Basic Average Shares |
|
7.33
-23.50%
|
9.58
-50.84%
|
19.49
+25.56%
|
15.52
|
| Diluted Average Shares |
|
7.33
-23.50%
|
9.58
-50.84%
|
19.49
+25.56%
|
15.52
|
| Diluted NI Availto Com Stockholders |
|
23.36
+235.53%
|
-17.24
-299.38%
|
-4.32
-1.81%
|
-4.24
|
| Gain On Sale Of PPE |
|
0.00
+100.00%
|
-1.57
|
0.00
|
—
|
| Preferred Stock Dividends |
|
1.13
-55.13%
|
2.52
|
—
|
—
|
| Line Item | Trend | 2025-04-30 | 2024-04-30 | 2023-04-30 |
|---|---|---|---|---|
| Total Assets |
|
55.17
-7.91%
|
59.90
-18.25%
|
73.28
|
| Current Assets |
|
22.38
-55.64%
|
50.44
-25.98%
|
68.15
|
| Cash Cash Equivalents And Short Term Investments |
|
15.54
-69.03%
|
50.18
-26.25%
|
68.04
|
| Cash And Cash Equivalents |
|
15.17
-69.76%
|
50.18
-26.25%
|
68.04
|
| Cash Financial |
|
—
|
—
|
—
|
| Other Short Term Investments |
|
0.37
|
0.00
|
—
|
| Receivables |
|
3.70
|
0.00
|
—
|
| Prepaid Assets |
|
—
|
—
|
0.11
|
| Hedging Assets Current |
|
2.92
|
0.00
|
—
|
| Other Current Assets |
|
0.22
-13.87%
|
0.26
+141.27%
|
0.11
|
| Total Non Current Assets |
|
32.79
+246.50%
|
9.46
+84.51%
|
5.13
|
| Goodwill And Other Intangible Assets |
|
1.55
+0.00%
|
1.55
-56.35%
|
3.55
|
| Other Intangible Assets |
|
1.55
+0.00%
|
1.55
-56.35%
|
3.55
|
| Investments And Advances |
|
22.47
|
0.00
-100.00%
|
1.57
|
| Other Non Current Assets |
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
|
| Total Liabilities Net Minority Interest |
|
3.28
-83.93%
|
20.39
+3375.95%
|
0.59
|
| Current Liabilities |
|
2.91
-60.73%
|
7.42
+1165.17%
|
0.59
|
| Payables And Accrued Expenses |
|
2.91
+159.15%
|
1.12
+91.72%
|
0.59
|
| Payables |
|
0.42
-41.79%
|
0.73
+291.38%
|
0.19
|
| Accounts Payable |
|
0.40
+2.53%
|
0.39
+203.53%
|
0.13
|
| Current Accrued Expenses |
|
2.49
+530.09%
|
0.40
-1.27%
|
0.40
|
| Total Tax Payable |
|
0.03
-92.52%
|
0.34
+485.36%
|
0.06
|
| Other Current Liabilities |
|
—
|
6.30
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.36
-97.20%
|
12.97
|
0.00
|
| Stockholders Equity |
|
51.89
+31.32%
|
39.51
-45.64%
|
72.69
|
| Common Stock Equity |
|
51.89
+87.69%
|
27.65
-61.97%
|
72.69
|
| Capital Stock |
|
0.00
-99.98%
|
11.87
+549399.21%
|
0.00
|
| Common Stock |
|
0.00
+0.00%
|
0.00
+0.32%
|
0.00
|
| Preferred Stock |
|
0.00
-100.00%
|
11.87
|
0.00
|
| Share Issued |
|
21.67
+0.00%
|
21.67
+0.32%
|
21.60
|
| Ordinary Shares Number |
|
6.80
-15.45%
|
8.04
-52.14%
|
16.79
|
| Treasury Shares Number |
|
14.88
+9.11%
|
13.63
+183.57%
|
4.81
|
| Additional Paid In Capital |
|
181.49
-2.07%
|
185.33
-8.36%
|
202.23
|
| Retained Earnings |
|
-84.97
+26.51%
|
-115.63
+0.29%
|
-115.96
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.02
-1.52%
|
-0.02
-2.21%
|
-0.02
|
| Treasury Stock |
|
44.61
+6.11%
|
42.04
+210.02%
|
13.56
|
| Other Equity Adjustments |
|
-0.02
-1.52%
|
-0.02
-2.21%
|
-0.02
|
| Total Equity Gross Minority Interest |
|
51.89
+31.32%
|
39.51
-45.64%
|
72.69
|
| Total Capitalization |
|
51.89
+31.32%
|
39.51
-45.64%
|
72.69
|
| Working Capital |
|
19.46
-54.76%
|
43.02
-36.33%
|
67.56
|
| Invested Capital |
|
51.89
+87.69%
|
27.65
-61.97%
|
72.69
|
| Net Tangible Assets |
|
50.34
+32.60%
|
37.97
-45.09%
|
69.14
|
| Tangible Book Value |
|
50.34
+92.89%
|
26.10
-62.25%
|
69.14
|
| Derivative Product Liabilities |
|
0.34
-97.39%
|
12.97
|
0.00
|
| Financial Assets |
|
8.76
+70.07%
|
5.15
|
0.00
|
| Non Current Accrued Expenses |
|
0.03
|
0.00
|
—
|
| Non Current Note Receivables |
|
0.00
-100.00%
|
2.75
|
0.00
|
| Notes Receivable |
|
3.70
|
0.00
|
—
|
| Preferred Stock Equity |
|
—
|
11.87
|
—
|
| Line Item | Trend | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-2.98
-38.43%
|
-2.15
+43.29%
|
-3.79
+7.86%
|
-4.12
|
| Cash Flow From Continuing Operating Activities |
|
-2.98
-38.43%
|
-2.15
+43.29%
|
-3.79
+7.86%
|
-4.12
|
| Net Income From Continuing Operations |
|
30.66
+9084.98%
|
0.33
+107.73%
|
-4.32
-1.81%
|
-4.24
|
| Other Non Cash Items |
|
-21.23
-10785.50%
|
-0.20
-212.05%
|
0.17
+399.40%
|
0.03
|
| Stock Based Compensation |
|
0.48
-29.06%
|
0.67
+4.54%
|
0.65
+727.91%
|
0.08
|
| Asset Impairment Charge |
|
0.00
-100.00%
|
2.00
|
0.00
|
—
|
| Operating Gains Losses |
|
-8.17
-95.73%
|
-4.17
|
—
|
—
|
| Gain Loss On Investment Securities |
|
-8.17
-42.18%
|
-5.75
|
—
|
—
|
| Unrealized Gain Loss On Investment Securities |
|
-6.07
-457.51%
|
-1.09
|
0.00
|
—
|
| Change In Working Capital |
|
1.36
+353.78%
|
0.30
+200.58%
|
-0.30
-3387.23%
|
0.01
|
| Change In Prepaid Assets |
|
0.04
+123.69%
|
-0.15
-1026.06%
|
-0.01
+35.80%
|
-0.02
|
| Change In Payables And Accrued Expense |
|
1.32
+192.74%
|
0.45
+259.00%
|
-0.28
-1033.17%
|
0.03
|
| Change In Accrued Expense |
|
1.31
+589.99%
|
0.19
+566.54%
|
-0.04
-1406.07%
|
-0.00
|
| Change In Payable |
|
0.01
-96.23%
|
0.26
+207.47%
|
-0.24
-833.98%
|
0.03
|
| Change In Account Payable |
|
0.01
-96.23%
|
0.26
+207.47%
|
-0.24
-833.98%
|
0.03
|
| Change In Other Current Assets |
|
—
|
—
|
0.00
+100.00%
|
-0.00
|
| Investing Cash Flow |
|
-7.00
-40.00%
|
-5.00
|
0.00
|
0.00
|
| Cash Flow From Continuing Investing Activities |
|
-7.00
-40.00%
|
-5.00
|
0.00
|
—
|
| Net Investment Purchase And Sale |
|
-7.00
|
0.00
|
0.00
|
—
|
| Purchase Of Investment |
|
-7.00
|
0.00
|
—
|
—
|
| Net Other Investing Changes |
|
—
|
-5.00
|
—
|
—
|
| Financing Cash Flow |
|
-25.03
-133.74%
|
-10.71
+21.03%
|
-13.56
-115.53%
|
87.31
|
| Cash Flow From Continuing Financing Activities |
|
-25.03
-133.74%
|
-10.71
+21.03%
|
-13.56
-115.53%
|
87.31
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
0.00
+100.00%
|
-0.05
|
| Repayment Of Debt |
|
—
|
—
|
0.00
+100.00%
|
-0.05
|
| Long Term Debt Payments |
|
—
|
—
|
0.00
+100.00%
|
-0.05
|
| Net Long Term Debt Issuance |
|
—
|
—
|
0.00
+100.00%
|
-0.05
|
| Net Common Stock Issuance |
|
-2.54
+90.98%
|
-28.20
-107.94%
|
-13.56
-115.52%
|
87.36
|
| Common Stock Payments |
|
-2.54
+90.98%
|
-28.20
-107.94%
|
-13.56
|
0.00
|
| Repurchase Of Capital Stock |
|
-25.03
+43.57%
|
-44.36
-227.11%
|
-13.56
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.00
-100.00%
|
0.00
-92.05%
|
0.00
|
0.00
|
| Changes In Cash |
|
-35.01
-96.02%
|
-17.86
-2.92%
|
-17.35
-120.86%
|
83.19
|
| Effect Of Exchange Rate Changes |
|
-0.00
+29.53%
|
-0.00
+92.99%
|
-0.01
-256.67%
|
0.00
|
| Beginning Cash Position |
|
50.18
-26.25%
|
68.04
-20.33%
|
85.40
+3778.14%
|
2.20
|
| End Cash Position |
|
15.17
-69.76%
|
50.18
-26.25%
|
68.04
-20.33%
|
85.40
|
| Free Cash Flow |
|
-2.98
-38.43%
|
-2.15
+43.29%
|
-3.79
+7.86%
|
-4.12
|
| Interest Paid Supplemental Data |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
-100.00%
|
0.00
|
0.00
-100.00%
|
0.00
|
| Common Stock Issuance |
|
—
|
—
|
0.00
-100.00%
|
87.36
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
33.65
|
0.00
-100.00%
|
87.36
|
| Net Preferred Stock Issuance |
|
-22.49
-228.57%
|
17.49
|
0.00
|
—
|
| Preferred Stock Issuance |
|
0.00
-100.00%
|
33.65
|
0.00
|
—
|
| Preferred Stock Payments |
|
-22.49
-39.15%
|
-16.16
|
0.00
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-02 View
- 42026-04-02 View
- 42026-04-02 View
- 42026-04-02 View
- 8-K2026-04-02 View
- 42026-03-18 View
- 10-Q2026-03-17 View
- 42026-01-07 View
- 42026-01-07 View
- 10-Q2025-12-18 View
- 42025-12-12 View
- 42025-12-12 View
- 42025-12-12 View
- 42025-12-12 View
- 42025-12-12 View
- 8-K2025-12-05 View
- 42025-11-18 View
- 8-K2025-10-31 View
- 10-Q2025-09-15 View
- 8-K2025-09-05 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|